Accueil >
Publications >
Platelet activation in critically ill COVID-19 patients

Platelet activation in critically ill COVID-19 patients

17 juil. 2021Annals of Intensive Care

Auteurs

Nader Yatim, Jeremy Boussier, Richard Chocron, Jérôme Hadjadj, Aurélien Philippe, Nicolas Gendron, Laura Barnabei, Bruno Charbit, Tali-Anne Szwebel, Nicolas Carlier, Frédéric Pène, Célia Azoulay, Lina Khider, Tristan Mirault, Jean-Luc Diehl, Coralie L. Guerin, Frédéric Rieux-Laucat, Darragh Duffy, Solen Kernéis, David M. Smadja, Benjamin Terrier

Résumé

Abstract

Background

Microvascular, arterial and venous thrombotic events have been largely described during severe coronavirus disease 19 (COVID-19). However, mechanisms underlying hemostasis dysregulation remain unclear.

Methods

We explored two independent cross-sectional cohorts to identify soluble markers and gene-expression signatures that discriminated COVID-19 severity and outcomes.

Results

We found that elevated soluble (s)P-selectin at admission was associated with disease severity. Elevated sP-selectin was predictive of intubation and death (ROC AUC = 0.67, p = 0.028 and AUC = 0.74, p = 0.0047, respectively). An optimal cutoff value was predictive of intubation with 66% negative predictive value (NPV) and 61% positive predictive value (PPV), and of death with 90% NPV and 55% PPV. An unbiased gene set enrichment analysis revealed that critically ill patients had increased expression of genes related to platelet activation. Hierarchical clustering identified ITG2AB, GP1BB, PPBP and SELPLG to be upregulated in a grade-dependent manner. ROC curve analysis for the prediction of intubation was significant for SELPLG and PPBP (AUC = 0.8, p = 0.046 for both). An optimal cutoff value for PBPP was predictive of intubation with 100% NPV and 45% PPV, and for SELPLG with 100% NPV and 50% PPV.

Conclusion

We provide evidence that platelets contribute to COVID-19 severity. Plasma sP-selectin level was associated with severity and in-hospital mortality. Transcriptional analysis identified PPBP/CXCL7 and SELPLG as biomarkers for intubation. These findings provide additional evidence for platelet activation in driving critical COVID-19. Specific studies evaluating the performance of these biomarkers are required.